About us
Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.
- Website
-
https://www.curie.bio
External link for Curie.Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Remote
- Type
- Privately Held
- Founded
- 2022
Locations
-
Primary
Remote, US
Employees at Curie.Bio
-
B. Christopher Kim
Executive at Bridge Biotherapeutics
-
John Herrmann
SVP, Portfolio Insights & Market Intelligence at Curie.Bio
-
Pallavur Sivakumar
Biotech Venture Capital | Curie.bio BIOTECHNOLOGY/ PHARMACEUTICAL LEADER| Biologics | Cell Therapy | Degraders/Small Molecules| Discovery and…
-
Christina Majer
Updates
-
“I am a problem solver. It’s amazing how often a seemingly very complex problem has a surprisingly simple, elegant solution. The key to finding these solutions is asking the right questions.” After spending the last 8 years managing drug discovery projects at Novartis and contributing to multiple approved drugs, Jeroen Verheijen now lends his expertise to every set of founders we support. He shares details on the Curie.Bio website. https://lnkd.in/eDXBgMEX
-
“How can we make it happen?" That's the first question Katharina Kreymborg asks when she sees a new proposal from founders. From leading cancer immunotherapy research at Roche to building new companies at Versant Ventures, she has seen the drug development journey from many different angles. Now, she leverages these learnings to help founders at Curie.Bio create companies that are "scientifically exciting, financially profitable and operationally sound." Read more about Nina on our website. https://lnkd.in/gZpXB6QA
-
"Million Dollar Meetings" - This is what co-piloting with Curie.Bio truly looks like. Before we’ve even made an investment, Curie.Bio gives founders access to a world-class team of experts that would otherwise cost millions to recruit and retain. Pictured here is the team we dedicated to supporting one of our portfolio companies during the planning phase, pre-investment. This level of support ensures founders have the best possible chance to develop impactful medicines. After we've invested, our weekly meetings with portfolio companies typically involve 10-20 members from our team and private network, all focused on advancing workstreams to achieve critical, value-inflecting milestones.
-
"Drug discovery is akin to an extreme sport, where the exhilaration comes from being part of a team willing to take risks, tackle intricate challenges, and ultimately craft medicines that enhance human health." This insight comes from Wenyan Miao, who has recently joined our co-pilot team, bringing 25 years of experience in driving innovation in #autoimmune and #inflammatory disease therapies. Wenyan shares more about her passion for supporting Curie.Bio founders here. https://lnkd.in/gYzyf8NZ
-
Every founder we support hopes to invent a blockbuster medicine that saves the lives of thousands of patients. At Curie.Bio, we think the best way of helping founders accomplish that goal is by pairing them up with people who have already done it. Gregory Carven, Partner at Curie.Bio, led the discovery of Keytruda™ and was an early champion for #immunooncology at a time when most were unconvinced. He shares more about his passion for innovative science in service of patients on our website: https://lnkd.in/ehhZbAT3
-
Dennis Zaller has dedicated over 30 years to the discovery and development of new drugs that modify the immune system to help patients. In his own words, "The human immune system is incredibly powerful in the protection that it affords and the damage that it can inflict, so understanding how it works reveals a plethora of opportunities to find drugs." Check out highlights of Dennis' impressive career below, and read more here. https://lnkd.in/egmTWce2
-
Curie.Bio co-founder and CSO Christoph Lengauer has contributed to the discovery, development and approval of 10 drugs on the market today. He hopes that Curie.Bio can significantly improve founders’ abilities to create impactful medicines while minimizing long-term dilution. He shares more here. https://lnkd.in/eg3qNVr7
-
"At Curie.Bio, I’m excited to be part of the endless possibilities that open up when you combine innovative ideas, cutting-edge technology, and experienced drug hunters, which I believe will lead to the discovery of new therapeutics at a speed and scale that has not been possible before,” says Curie.Bio SVP, CSO Partner Team Susan Wee. Sue is a seasoned expert in translating basic research to the discovery of new oncology drugs. Read more about the expertise she brings to our team of drug hunters on our website. https://lnkd.in/ejADGMvr
-
Curie.Bio founders Zach Weinberg and Alexis Borisy joined the STAT Readout LOUD team to share more on our mission to #FreeTheFounders. Listen below (starting at 21:00) for insight into what sets Curie.Bio apart from other VC firms and the opportunities our new $380M Pro Rata Series A fund will allow.